Cue Biopharma (CUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cue Biopharma (CUE) has a cash flow conversion efficiency ratio of -0.681x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.02 Million) by net assets ($13.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CUE net asset quality score to measure how much of total assets are equity-financed.
Cue Biopharma - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Cue Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CUE cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cue Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cue Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pennon Group Plc
LSE:PNN
|
0.122x |
|
Wave Electronics Co. Ltd
KQ:095270
|
-0.004x |
|
C-Com Satellite Systems Inc.
V:CMI
|
-0.001x |
|
Progressive Planet Solutions Inc
V:PLAN
|
0.088x |
|
Samil Enterprise Co. Ltd
KQ:002290
|
0.033x |
|
Morphic Ethical Equities Fund Ltd
AU:MEC
|
0.049x |
|
Inmobiliaria Park Rose Iberoamericana SOCIMI SA
MC:YPARK
|
0.003x |
|
Tien Wah Press Holdings Bhd
KLSE:7374
|
0.095x |
Annual Cash Flow Conversion Efficiency for Cue Biopharma (2015–2024)
The table below shows the annual cash flow conversion efficiency of Cue Biopharma from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see CUE market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.50 Million | $-36.33 Million | -2.076x | -92.66% |
| 2023-12-31 | $37.09 Million | $-39.96 Million | -1.078x | -69.30% |
| 2022-12-31 | $65.68 Million | $-41.81 Million | -0.636x | -7.33% |
| 2021-12-31 | $65.49 Million | $-38.84 Million | -0.593x | -44.01% |
| 2020-12-31 | $78.91 Million | $-32.49 Million | -0.412x | +27.02% |
| 2019-12-31 | $54.58 Million | $-30.80 Million | -0.564x | +27.43% |
| 2018-12-31 | $33.97 Million | $-26.41 Million | -0.777x | -292.87% |
| 2017-12-31 | $61.61 Million | $-12.19 Million | -0.198x | +49.69% |
| 2016-12-31 | $15.17 Million | $-5.97 Million | -0.393x | -64.64% |
| 2015-12-31 | $6.94 Million | $-1.66 Million | -0.239x | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more